ClinicalTrials.gg
RecruitingNCT07296835Updated May 6, 2026

Surgical Outcomes and Costs in Using the Shenzhen HugeMed 6.3 French Flexible Ureteroscope

An interventional study of Ureteroscopy using the 6.3 Fr f-URS hugemed and Hugemed 6.3 Fr f-URS in Kidney Stones, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University of Kansas Medical Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 193 studies in Kidney Calculi with a site in United States — 42 open to participants now, 58 under way, none of them phase 3. Kidney Calculi · United States.

Planned enrollment
61st of 165
75 · median 47
Started
2026
with 13 others
No phase
113 of 193
29 open now
Primary completion
2026-11
later than 20 of 57 live
Registered
182nd of 193
by date
Lead sponsor
6 of 193
University of Kansas Medical Center

Among the 193 studies in Kidney Calculi with a site in United States, this one is the 61st largest by planned enrollment of the 165 interventional ones that give a count, is one of 14 that started in 2026, is one of 113 with no phase, reaches primary completion later than 20 of the 57 other live ones, and was the 182nd registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

42 of the 193 studies in Kidney Calculi with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Kidney Calculi with a site in United States, or all of them as a file.
02

Study summary

Comprehensive comparative investigations between HugeMed HU30M 6.3 Fr f-URS and traditional approach f-URS devices in RIRS are lacking in an American population. The investigators aim to compare the outcomes of using the 6.3 Fr f-URS versus traditional approach (other f-URS present in our institution) to treat patients with stone burden ≤ 2.5 cm. The findings of this study will expand on the potential advantages and drawbacks of HU30M in enhancing surgical outcomes and patient safety in RIRS procedures. We hypothesize that the use of the HU30M will result in increased cost savings while providing similar stone free rates when compared to traditionally used f-URS devices.

03

Conditions studied

  • Kidney Stones

Browse trials for

Keywords

  • hugemed, coast saving, ureteroscopy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females ≥ 18 years of age
  • Patients with ureteral or kidney stones undergoing primary flexible ureteroscopy for retrograde intrarenal surgery
  • Total stone burden ≤ 2.5 cm

Exclusion criteria

Exclusion Criteria:

  • Undergoing bilateral stone treatment during the same procedure
  • Patients with known genitourinary anatomical abnormalities that would complicate the procedure as determined by the treating investigator
  • Uncorrected coagulopathy
  • Patients with urinary diversions
  • Chronic external urinary catheters
  • Women who are pregnant
  • patients
  • Non-elective procedures
  • Participants must not be involved in any other clinical research studies during the duration of this trial. Exceptions may be made if the investigator determines, on a case-by-case basis, that participation in another study will not adversely affect the outcomes or integrity of this trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    hugemed ureteroscopy

    Patients scheduled to undergo URS retrograde intrarenal surgery per standard of care will be recruited from urology clinics or OR schedules using using the 6.3 Fr f-URS . Patients may be approached and consented in clinic or pre-op. All procedures, devices, and ancillary equipment are standard of care. There is no additional cost to the patient, only the typical standard of care costs. Participants will not be compensated for participation in the study.

    Device: Ureteroscopy using the 6.3 Fr f-URS hugemed · Device: Hugemed 6.3 Fr f-URS

Interventions

  • DeviceUreteroscopy using the 6.3 Fr f-URS hugemed

    All patients will be counseled on standard treatment options. Treatment options and subsequent care will not deviate from routine care. If they do not enroll in the study, the HU30M may still be used during routine surgery and care. The only intervention specific to the research will involve the use of patient information in describing the results. Participants will undergo RIRS in standard fashion, without deviation from the standard of care. Patients will be brought to the operating room, positioned, and placed under general anesthesia. RIRS will be performed using HU30M 6.3 Fr f-URS. Laser platform (ex: HoYAG or TFL) as well as laser settings will be at the treating investigator's discretion and may be changed during the procedure at their discretion as well, all per standard of care. The initial laser settings and changes that occurred to the settings after the first minute of the case will be recorded.

  • DeviceHugemed 6.3 Fr f-URS

    Retrograde intrarenal surgery will be performed using HU30M 6.3 Fr f-URS.

06

What researchers measure

Primary outcomes

  1. To evaluate and compare outcomes and costs associated with hugeMed 6.3 Fr flexible URS versus traditional approach in RIRS

    Stone free rate, defined as the absence of residual stone fragments \> 2 mm, as determined by noncontrast CT scan performed

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — data will be used to compare different outcomes from ureteroscopy surgeries

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Nov 2026, 6 months later.

Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 6 months is below that.

Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 22, 2025
StartEst.
May 1, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07296835
Collaborators
HugeMed
Responsible party
Wilson Molina (Professor, University of Kansas Medical Center) — Principal investigator
First posted
Dec 22, 2025
Start date
May 1, 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Nov 2028 (estimated)
Last update
May 6, 2026

Study contacts

Wilson R. Molina, MD
Contact
wmolina@kumc.edu
913-588-8721
Jane Research Project Manager
Contact
jledesma2@kumc.edu
913-588-8721
Wilson R. Molina, MD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion